Physiological parameter confidence measure

Information

  • Patent Grant
  • 7957780
  • Patent Number
    7,957,780
  • Date Filed
    Wednesday, March 1, 2006
    18 years ago
  • Date Issued
    Tuesday, June 7, 2011
    13 years ago
Abstract
Confidence in a physiological parameter is measured from physiological data responsive to the intensity of multiple wavelengths of optical radiation after tissue attenuation. The physiological parameter is estimated based upon the physiological data. Reference data clusters are stored according to known values of the physiological parameter. At least one of the data clusters is selected according to the estimated physiological parameter. The confidence measure is determined from a comparison of the selected data clusters and the physiological data.
Description
CORPORATION BY REFERENCE OF COPENDING RELATED APPLICATIONS


















application






Ser. No.
Filing Date
Title





















1
11/367,013
Mar. 1, 2006
Multiple Wavelength






Sensor Emitters



2
11/366,995
Mar. 1, 2006
Multiple Wavelength






Sensor Equalization



3
11/366,209
Mar. 1, 2006
Multiple Wavelength






Sensor Substrate



4
11/366,210
Mar. 1, 2006
Multiple Wavelength






Sensor Interconnect



5
11/366,833
Mar. 1, 2006
Multiple Wavelength






Sensor Attachment



6
11/366,997
Mar. 1, 2006
Multiple Wavelength






Sensor Drivers



7
11/367,036
Mar. 1, 2006
Configurable Physiological






Measurement System



8
11/367,033
Mar. 1, 2006
Noninvasive Multi-






Parameter Patient Monitor



9
11/367,014
Mar. 1, 2006
Noninvasive Multi-






Parameter Patient Monitor



10
11/366,208
Mar. 1, 2006
Noninvasive Multi-






Parameter Patient Monitor











The present application incorporates the foregoing disclosures herein by reference.


BACKGROUND OF THE INVENTION

Spectroscopy is a common technique for measuring the concentration of organic and some inorganic constituents of a solution. The theoretical basis of this technique is the Beer-Lambert law, which states that the concentration ci of an absorbent in solution can be determined by the intensity of light transmitted through the solution, knowing the pathlength dλ, the intensity of the incident light I0,λ, and the extinction coefficient εi,λ at a particular wavelength λ. In generalized form, the Beer-Lambert law is expressed as:










I
λ

=


I

0
,
λ







-

d
λ


·

μ

a
,
λ









(
1
)







μ

a
,
λ


=




i
=
1

n




ɛ

i
,
λ


·

c
i







(
2
)








where μα,λ is the bulk absorption coefficient and represents the probability of absorption per unit length. The minimum number of discrete wavelengths that are required to solve EQS. 1-2 are the number of significant absorbers that are present in the solution.


A practical application of this technique is pulse oximetry, which utilizes a noninvasive sensor to measure oxygen saturation (SpO2) and pulse rate. In general, the sensor has light emitting diodes (LEDs) that transmit optical radiation of red and infrared wavelengths into a tissue site and a detector that responds to the intensity of the optical radiation after absorption (e.g., by transmission or transreflectance) by pulsatile arterial blood flowing within the tissue site. Based on this response, a processor determines measurements for SpO2, pulse rate, and can output representative plethysmographic waveforms. Thus, “pulse oximetry” as used herein encompasses its broad ordinary meaning known to one of skill in the art, which includes at least those noninvasive procedures for measuring parameters of circulating blood through spectroscopy. Moreover, “plethysmograph” as used herein (commonly referred to as “photoplethysmograph”), encompasses its broad ordinary meaning known to one of skill in the art, which includes at least data representative of a change in the absorption of particular wavelengths of light as a function of the changes in body tissue resulting from pulsing blood.


Pulse oximeters capable of reading through motion induced noise are available from Masimo Corporation (“Masimo”) of Irvine, Calif. Moreover, portable and other oximeters capable of reading through motion induced noise are disclosed in at least U.S. Pat. Nos. 6,770,028, 6,658,276, 6,157,850, 6,002,952 5,769,785, and 5,758,644, which are owned by Masimo and are incorporated by reference herein. Such reading through motion oximeters have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.



FIG. 1 illustrates HbO2 and Hb absorption μα versus wavelength. At red and near IR wavelengths below 970 nm, where water has a significant peak, Hb and HbO2 are the only significant absorbers normally present in the blood. Thus, typically only two wavelengths are needed to resolve the concentrations of Hb and HbO2, e.g. a red (RD) wavelength at 660 nm and an infrared (IR) wavelength at 940 nm. In particular, SpO2 is computed based upon a red ratio RedAC/RedDC and an IR ratio IRAC/IRDC, which are the AC detector response magnitude at a particular wavelength normalized by the DC detector response at that wavelength. The normalization by the DC detector response reduces measurement sensitivity to variations in tissue thickness, emitter intensity and detector sensitivity, for example. The AC detector response is a plethysmograph, as described above. Thus, the red and IR ratios can be denoted as NPRD and NPIR respectively, where NP stands for “normalized plethysmograph.” In pulse oximetry, oxygen saturation is calculated from the ratio NPRD/NPIR.


SUMMARY OF THE INVENTION

A multiple wavelength sensor and a noninvasive multi-parameter patient monitor, such as referenced above, make blood absorption measurements at more than a red wavelength and an IR wavelength. In one embodiment, described below, blood absorption measurements are made at eight wavelengths. Advantageously, this rich wavelength data, compared with conventional pulse oximetry, allows a determination of a tissue profile or tissue characterization over a wavelength spectrum.



FIG. 2 illustrates an example of a “tissue profile” 200 for SpO2=97%. For this example, including FIGS. 3-4, below, the sensor emits eight wavelengths (610, 620, 630, 655, 700, 720, 800 and 905 nm). The graph is a plot of NP ratios 210 versus wavelength 220, where the NP ratios are of the form NPλ1/NPλ2. This is a generalization to multiple wavelengths of the ratio NPRD/NPIR described above for two (red and IR) wavelengths. In order to provide a common scale for these NP ratios, the ratios are calculated with respect to a reference wavelength, λr, which may be any of the available wavelengths. Thus, the plotted NP ratios are denoted NPλn/NPλr over the n available wavelengths, including λr. Note that the NP ratio at the reference wavelength is NPλr/NPλr=1, which is 800 nm in FIG. 2.


As shown in FIG. 2, when a sensor is properly positioned on a tissue site, the detector only receives LED emitted light that has propagated through the tissue site after tissue scattering and absorption. Thus, a tissue profile 200 should reflect the blood constituent absorption characteristics illustrated in FIG. 1, above. For this high oxygen saturation (97%) example, HbO2 is the only significantly absorbing blood constituent and, indeed, the resulting tissue profile 200 is shaped like the HbO2 absorption curve 110 (FIG. 1).





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a graph of oxyhemoglobin and reduced hemoglobin light absorption versus wavelength across portions of the red and IR spectrum;



FIG. 2 is a graph of NP ratios versus wavelength illustrating a tissue profile;



FIG. 3 is a graph of NP ratios versus wavelength illustrating a probe-off profile;



FIG. 4 is a graph of NP ratios versus wavelength illustrating a penumbra profile;



FIG. 5 is a general block diagram of a confidence measurement system;



FIG. 6 is a graph of normalized plethysmograph (NP) ratios versus wavelength for low and high SpO2 illustrating a NP envelope;



FIG. 7 is a block diagram of a multiple wavelength probe off detector utilizing an NP envelope;



FIG. 8 is a graph of NP ratios versus wavelength illustrating a family of parametric NP curves;



FIG. 9 is a block diagram of a multiple wavelength confidence measurement system utilizing parametric NP curves;



FIG. 10 is an NP ratio graph illustrating a family of NP data clusters; and



FIG. 11 is a block diagram of a multiple wavelength confidence measurement system utilizing NP data clusters.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In this application, reference is made to many blood parameters. Some references that have common shorthand designations are referenced through such shorthand designations. For example, as used herein, HbCO designates carboxyhemoglobin, HbMet designates methemoglobin, and Hbt designates total hemoglobin. Other shorthand designations such as COHb, MetHb, and tHb are also common in the art for these same constituents. These constituents are generally reported in terms of a percentage, often referred to as saturation, relative concentration or fractional saturation. Total hemoglobin is generally reported as a concentration in g/dL. The use of the particular shorthand designators presented in this application does not restrict the term to any particular manner in which the designated constituent is reported.



FIG. 3 illustrates an example of a probe-off profile 300. When a sensor is completely dislodged from a patient, a so-called “probe off” condition occurs. Despite a probe off condition, an optical sensor may continue to detect an AC signal, which can be induced at the detector by other than pulsatile arterial absorption of LED emitted light. For example, small patient movements, vibrations, air flow or other perturbations may cause the pathlength between the LEDs and the detector to vary, resulting in an AC detector signal that can be mistakenly interpreted by the monitor as due to pulsatile arterial blood. Further, ambient light may reach the detector, and any modulation of the ambient light due to AC power, power fluctuations, moving objects, such as a fan, among other perturbations can be also mistaken as a pulsatile arterial signal. Probe off errors are serious because a blood constituent monitor may display normal results, such as oxygen saturation, when, in fact, the sensor is not properly attached to the patient, potentially leading to missed severe desaturation events. As shown in FIG. 3, a probe-off profile 300 is readily apparent as it does not have a shape related to the absorption characteristics of hemoglobin constituents.



FIG. 4 illustrates an example of a penumbra profile 400. When a sensor is not properly positioned or becomes partially dislodged, a penumbra condition may occur, where the detector is “shadowed” by a tissue site, such as a finger, but also receives some light directly from the emitters or indirectly reflected off the sensor housing, or both. As a result, the DC signal at the detector rises significantly, which lowers the AC/DC ratio (NP). Because red wavelengths are more significantly absorbed by Hb and HbO2, the penumbra condition is most noticeable at the red portion 405 of the NPλn/ NPλr. This effect is readily seen in the penumbra profile 400 as compared to a normal tissue profile 200 (FIG. 2).


Advantageously, a physiological parameter confidence measurement system, as described below, can distinguish a tissue profile 200 (FIG. 2) from a probe-off profile 300 (FIG. 3) or penumbra profile 400 (FIG. 4), as examples. Further, a physiological parameter confidence measurement system can provide indications that the detector signal is degraded as the result of various physiological and non-physiological phenomenon.



FIG. 5 illustrates a physiological parameter confidence measurement system 500 having a physiological data 510 input, a confidence indicator 560 output and a probe-off indicator 570 output. In one embodiment, physiological data 510, such as the NP ratios described above, is derived from a sensor 501 generating a sensor signal 502 responsive to multiple wavelengths of optical radiation transmitted into and attenuated by a tissue site. The confidence indicator 560 provides an observer with some measure of “goodness” for the physiological data 510. That is, if confidence is high, it is likely the physiological data 510 is representative of a physiological condition or state. If confidence is low, the physiological data 510 may be less representative of a physiological condition or state. If the confidence is very low, a probe-off indicator 570 may be generated to alert an observer to the possibility that a sensor from which the physiological data 510 is derived is not properly positioned on a tissue site and may not be generating physiologically significant data. In one embodiment, a confidence measure may be provided as a percentage, such as 0-100%. In various embodiments, a confidence indicator 560 corresponding to a confidence measure may be visual or audible or both. For example, a confidence indicator 560 may be a number display, a display message, a bar display, a color indicator or display, such as green (high confidence), yellow (average confidence), red (low confidence). Also, a confidence indicator 560 may be any of various alarm sounds, tones or patterns of sounds or tones, such as a double beep at less than high confidence. In one embodiment, the physiological parameter confidence measurement system 500 is incorporated within a physiological monitor 503 having a display 580 or alarm 590 for outputting the confidence indicator 560 or probe-off indicator 570.


As shown in FIG. 5, the physiological parameter confidence measurement system 500 also has a parameter estimator 520, a physiological data reference 540 and a confidence measurer 550. The parameter estimator 520 derives one or more physiological parameter estimates, {circumflex over (P)}, 530 based upon the physiological data 510. The parameter estimate or estimates 530 are used to select one or more data clusters 545 from the physiological data reference 540. In one embodiment, the physiological data reference 540 is a collection of predetermined physiological data organized in data clusters. For example the physiological data reference 540 may contain clinically-derived physiological data organized according to corresponding values of a physiological parameter determined by a “gold standard” instrument. In a particular embodiment, the physiological data are NP ratios obtained for various physiological parameters, such as SpO2, HbCO, HbMet, Hbt, fractional oxygen saturation, bilirubin or glucose to name a few, as measured with a standardized cooximeter, for example. In one embodiment, the physiological data reference 540 is a non-volatile memory or other data storage device containing predetermined physiological data. The confidence measurer 550 uses the physiological data 510 and the selected data cluster or data clusters 545 to generate the confidence indicator 560, the probe-off indicator 570 or both.


A confidence measurement and confidence indicator, as described herein, may be combined with other signal quality and data confidence measurements and indicators, such as those described in U.S. Pat. No. 6,996,427 titled Pulse Oximetry Data Confidence Indicator and U.S. Pat. No. 6,606,511 titled Pulse Oximetry Pulse Indicator, both patents assigned to Masimo Corporation, Irvine, Calif. and incorporated by reference herein. A probe off measurement and probe off indicator as described herein may be combined with other probe off measurements and indicators, such as those described in U.S. Pat. No. 6,654,624 titled Pulse Oximeter Probe-Off Detector and U.S. Pat. No. 6,771,994 titled Pulse Oximeter Probe-Off Detection System, both patents assigned to Masimo Corporation, Irvine, Calif. and incorporated by reference herein.



FIG. 6 illustrates NP ratio versus wavelength curves computed from a multiple wavelength sensor, such as described in the U.S. Patent Application titled Multiple Wavelength Sensor, referenced above. In this example, the sensor emits eight wavelengths (620, 630, 660, 700, 730, 805, 905 and 960 nm). Shown is a low oxygen saturation curve 610, e.g. SpO2=70% and a high oxygen saturation curve 620, e.g. SpO2≈100%. By comparison, a conventional two wavelength pulse oximetry sensor, as described above, results in a single point on a particular curve. Advantageously, the NP ratio curves 610, 620 represent a tissue profile that can be compared to a particular sensor response to determine if a physiologically significant measurement has been made. In one embodiment, the NP ratio curves 610, 620 delineate the boundaries of a physiologically significant NP ratio region 630. Although described above with respect to SpO2, such regions or boundaries can be derived for other physiological parameters such as HbCO, HbMet, Hbt, fractional oxygen saturation, bilirubin or glucose to name a few.



FIG. 7 illustrates one embodiment of a physiological parameter confidence measurement system 700 utilizing a NP ratio region such as described with respect to FIG. 6, above. The confidence measurement system 700 has input NP ratios 710 measured in response to a multiple wavelength sensor, reference NP ratio region 740 that delineates physiologically significant NP ratios 630 (FIG. 6), and a comparator 750. In one particular embodiment, the NP ratio region 740 is predetermined from clinically-derived data for one or more parameters of interest, such as SpO2, HbCO, HbMet, Hbt, fractional oxygen saturation, bilirubin or glucose, to name a few. In another particular embodiment, the NP ratio region 740 is theoretically calculated. The comparator 750 compares the input NP ratios 710 with the NP ratio region 740 and generates a probe-off indicator 770 if any, or more than a predetermine number, of the input NP ratios 710 fall outside of an NP ratio region 740.



FIG. 8 illustrates a family of parametric NP ratio versus wavelength curves 800 computed from a multiple wavelength sensor, such as referenced above. Each curve represents a different value of a measured parameter, such as SpO2. For example, there may be a curve for each of SpO2=70%, 75%, 80%, . . . 100%. Advantageously, such curves more precisely indicate physiologically significant multiple wavelength sensor measurements as compared to a bounded NP ratio region 630 (FIG. 6) such as described with respect to FIGS. 6-7, above.



FIG. 9 illustrates another embodiment of a physiological parameter confidence measurement system 900 utilizing parametric NP ratio curves, such as described with respect to FIG. 8, above. The confidence measurement system 900 has input NP ratios 910 measured in response to a multiple wavelength sensor, a parameter estimator 920, reference parametric curves 940 and a difference calculator 950. The parameter estimator 920 inputs the NP ratios 910 so as to generate a parameter estimate 930, such as SpO2, HbCO, HbMet, Hbt, fractional oxygen saturation, bilirubin or glucose, to name a few. The estimated parameter 930 selects one or more of the reference parametric curves 940, which are predetermined from clinically-derived data that is stored in memory or data that is mathematically pre-calculated or calculated in real time and stored in memory. The difference calculator 950 measures the difference between the NP ratios 910 and the selected parametric curve 940. For example, a mean-squared error calculation can be made between the input NP ratios 910 and the selected parametric curve 945. The resulting difference calculation is used as a confidence measure or translated into a confidence measure and a confidence indicator output 960 is generated accordingly. Alternatively, or in addition to a confidence measure, a probe off condition can be indicated if the difference calculation is larger than a predetermined value or the confidence measure is less than a predetermined value. In another embodiment, a correlation calculator is used in place of the difference calculation.



FIG. 10 illustrates a family of data clusters 1000 shown in two dimensions by way of example. Each data cluster 1000 represents NP ratios clinically measured across a population for specific values 1020 of a selected parameter P, such as P1, P2, P3 and P4 as shown. Each data cluster 1000 defines a region 1010 of NP ratios measured for a particular parameter value 1020 and has a probability distribution, such as a normal distribution, over the indicated region 1010.


For example, the clinical data can be organized as a table of known values of P, corresponding NP ratios measured over a population, and the relative number of occurrences of particular NP ratio values for each value of P. The relative number of occurrences of particular NP ratio values for a particular value of P yields an NP ratio probability distribution for that value of P. Thus, each P value 1020 in the table has a corresponding data cluster 1000 of measured NP ratios and an associated probability distribution for those NP ratios.



FIG. 11 illustrates yet another embodiment of a physiological parameter confidence measurement system 1100 utilizing NP data clusters and corresponding probability distributions, such as described with respect to FIG. 10, above. The confidence measurement system 1100 has input NP ratios 1110 measured in response to a multiple wavelength sensor, a parameter estimator 1120, reference data clusters 1140 and a probability calculator 1150. The parameter estimator 1120 inputs the NP ratios 1110 so as to generate a parameter estimate 1130, such as described with respect to other embodiments, above. In one embodiment, the reference data clusters 1140, such as described with respect to FIG. 10, are stored in a memory device, such as an EPROM. The estimated parameter 1130 is compared with the reference data clusters 1140 so as to determine the closest region 1010 (FIG. 10) or closest overlapping portion of two regions 1010 (FIG. 10). The probability calculator 1150 computes a probability based upon the distribution above the selected region 1010 (FIG. 10). A confidence measure is also derived based upon the calculated probability 1150. In a particular embodiment, the confidence measure is the calculated probability. A confidence indicator 1160 is generated in response to the confidence measure. In one embodiment, if the confidence probability or the calculated confidence measure is below a predetermined threshold, a probe-off indicator 1170 is generated. In particular embodiments, the confidence indicator 1160 or probe-off indicator 1170 or both may be alphanumeric or digital displays, optical indicators or alarms or similar audible indicators, to name a few.


A physiological parameter confidence measurement system has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in art will appreciate many variations and modifications.

Claims
  • 1. A method of determining a measure of confidence in a physiological parameter, the physiological parameter determined by transmitting multiple wavelengths of optical radiation into a tissue site and detecting the optical radiation after tissue attenuation, the method comprising: deriving physiological data responsive to the intensity of multiple wavelengths of optical radiation transmitted into a tissue site and detected after tissue attenuation;estimating a physiological parameter based upon the physiological data;providing a physiological data reference;obtaining at least one data cluster from the physiological data reference wherein the at least one data cluster is a probability distribution of normalized pleth ratios; anddetermining a measure of confidence in the estimated physiological parameter based upon the at least one data cluster and the derived physiological data.
  • 2. The method according to claim 1 wherein the providing step comprises: predetermining the physiological data for known values of the physiological parameter across a sample population;clustering the data according to the physiological parameter values; andstoring the data clusters so as to be retrievable according to the physiological parameter values.
  • 3. The method according to claim 2 wherein the obtaining step comprises selecting the at least one data cluster according to the estimated physiological parameter.
  • 4. The method according to claim 3 wherein the selecting step comprises: determining at least one data cluster having a corresponding physiological parameter value closest to the estimated physiological parameter; andreading the determined at least one data cluster from the memory.
  • 5. The method according to claim 4 wherein the physiological parameter is at least one of SpO2, MetHb and HbCO.
  • 6. A physiological parameter confidence measurement method comprising: deriving physiological data responsive to the intensity of multiple wavelengths of optical radiation transmitted into a tissue site and detected after tissue attenuation;estimating a physiological parameter based upon the physiological data;providing a physiological data reference having a plurality of data clusters each corresponding to a particular value of the physiological parameter,;comparing at least one of the data clusters to the physiological data;indicating confidence in the estimated physiological parameter based upon the comparison; andassociating a probability function with each of the data clusters.
  • 7. The physiological parameter confidence measurement method according to claim 6 wherein the comparing step comprises determining a probability that the derived physiological data corresponds to the estimated physiological parameter.
  • 8. The physiological parameter confidence measurement method according to claim 7 wherein the indicating step comprises generating at least one of a visual indication and an audible indication corresponding to the determined probability.
  • 9. The physiological parameter confidence measurement method according to claim 8 further comprising triggering an alarm that a probe-off condition exists when the determined probability is below a predetermined threshold.
PRIORITY CLAIM TO RELATED PROVISIONAL APPLICATIONS

The present application claims priority benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 60/657,596, filed Mar. 1, 2005, entitled “Multiple Wavelength Sensor,” No. 60/657,281, filed Mar. 1, 2005, entitled “Physiological Parameter Confidence Measure,” No. 60/657,268, filed Mar. 1, 2005, entitled “Configurable Physiological Measurement System,” and No. 60/657,759, filed Mar. 1, 2005, entitled “Noninvasive Multi-Parameter Patient Monitor.” The present application incorporates the foregoing disclosures herein by reference.

US Referenced Citations (488)
Number Name Date Kind
3998550 Konishi et al. Dec 1976 A
4157708 Imura Jun 1979 A
4167331 Nielsen Sep 1979 A
4266554 Hamaguri May 1981 A
4446871 Imura May 1984 A
4586513 Hamaguri May 1986 A
4621643 New et al. Nov 1986 A
4653498 New et al. Mar 1987 A
4685464 Goldberger Aug 1987 A
4694833 Hamaguri Sep 1987 A
4700708 New et al. Oct 1987 A
4714341 Hamaguri et al. Dec 1987 A
4770179 New et al. Sep 1988 A
4773422 Isaacson et al. Sep 1988 A
4781195 Martin Nov 1988 A
4800885 Johnson Jan 1989 A
4832484 Aoyagi et al. May 1989 A
4846183 Martin Jul 1989 A
4863265 Flower et al. Sep 1989 A
4867571 Frick et al. Sep 1989 A
4869254 Stone et al. Sep 1989 A
4907876 Suzuki et al. Mar 1990 A
4911167 Corenman et al. Mar 1990 A
4934372 Corenman et al. Jun 1990 A
4942877 Sakai et al. Jul 1990 A
4955379 Hall Sep 1990 A
4960126 Conlon et al. Oct 1990 A
4960128 Gordon et al. Oct 1990 A
4964010 Miyasaka et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
4967571 Sporri Nov 1990 A
4975581 Robinson et al. Dec 1990 A
4986665 Yamanishi et al. Jan 1991 A
4997769 Lundsgaard Mar 1991 A
RE33643 Isaacson et al. Jul 1991 E
5033472 Sato et al. Jul 1991 A
5041187 Hink et al. Aug 1991 A
5054495 Uemura et al. Oct 1991 A
5058588 Kaestle et al. Oct 1991 A
5069213 Polczynski Dec 1991 A
5078136 Stone et al. Jan 1992 A
5163438 Gordon et al. Nov 1992 A
5190040 Aoyagi Mar 1993 A
5209230 Swedlow et al. May 1993 A
5259381 Cheung et al. Nov 1993 A
5267562 Ukawa et al. Dec 1993 A
5267563 Swedlow et al. Dec 1993 A
5278627 Aoyagi Jan 1994 A
5297548 Pologe Mar 1994 A
5313940 Fuse et al. May 1994 A
5331549 Crawford, Jr. Jul 1994 A
5335659 Pologe et al. Aug 1994 A
5337744 Branigan Aug 1994 A
5348004 Hollub Sep 1994 A
5351685 Potratz Oct 1994 A
5355880 Thomas et al. Oct 1994 A
5355882 Ukawa et al. Oct 1994 A
5361758 Hall et al. Nov 1994 A
5368224 Richardson et al. Nov 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5385143 Aoyagi Jan 1995 A
5387122 Goldberger et al. Feb 1995 A
5392777 Swedlow et al. Feb 1995 A
5413101 Sugiura May 1995 A
5421329 Casciani et al. Jun 1995 A
5427093 Ogawa et al. Jun 1995 A
5429128 Cadell et al. Jul 1995 A
5431170 Mathews Jul 1995 A
5435309 Thomas et al. Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
5452717 Branigan et al. Sep 1995 A
D363120 Savage et al. Oct 1995 S
RE35122 Corenman et al. Dec 1995 E
5482036 Diab et al. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5490523 Isaacson et al. Feb 1996 A
5494032 Robinson et al. Feb 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5503148 Pologe et al. Apr 1996 A
5520177 Ogawa May 1996 A
5533507 Potratz Jul 1996 A
5533511 Kaspari et al. Jul 1996 A
5551423 Sugiura Sep 1996 A
5553615 Carim et al. Sep 1996 A
5555882 Richardson et al. Sep 1996 A
5562002 Lalin Oct 1996 A
5577500 Potratz Nov 1996 A
5584299 Sakai et al. Dec 1996 A
5588427 Tien Dec 1996 A
5590649 Caro et al. Jan 1997 A
5590652 Inai Jan 1997 A
5595176 Yamaura Jan 1997 A
5596992 Haaland et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5603623 Nishikawa et al. Feb 1997 A
5630413 Thomas et al. May 1997 A
5632272 Diab et al. May 1997 A
5638816 Kiani-Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645059 Fein et al. Jul 1997 A
5645060 Yorkey Jul 1997 A
5645440 Tobler et al. Jul 1997 A
5660567 Nierlich et al. Aug 1997 A
5662106 Swedlow et al. Sep 1997 A
5676139 Goldberger et al. Oct 1997 A
5676141 Hollub Oct 1997 A
5678544 Delonzor et al. Oct 1997 A
5685299 Diab et al. Nov 1997 A
5685301 Klomhaus Nov 1997 A
5687719 Sato et al. Nov 1997 A
5687722 Tien et al. Nov 1997 A
5690104 Kanemoto et al. Nov 1997 A
5692503 Kuenstner Dec 1997 A
5697371 Aoyagi Dec 1997 A
5713355 Richardson et al. Feb 1998 A
D393830 Tobler et al. Apr 1998 S
5743262 Lepper, Jr. et al. Apr 1998 A
5743263 Baker, Jr. Apr 1998 A
5746206 Mannheimer May 1998 A
5746697 Swedlow et al. May 1998 A
5752914 Delonzor et al. May 1998 A
5755226 Carim et al. May 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5772587 Gratton et al. Jun 1998 A
5779630 Fein et al. Jul 1998 A
5782237 Casciani et al. Jul 1998 A
5782756 Mannheimer Jul 1998 A
5782757 Diab et al. Jul 1998 A
5785659 Caro et al. Jul 1998 A
5790729 Pologe et al. Aug 1998 A
5791347 Flaherty et al. Aug 1998 A
5792052 Isaacson et al. Aug 1998 A
5793485 Gourley Aug 1998 A
5800348 Kaestle et al. Sep 1998 A
5800349 Isaacson et al. Sep 1998 A
5803910 Potratz Sep 1998 A
5807246 Sakaguchi et al. Sep 1998 A
5807247 Merchant et al. Sep 1998 A
5810723 Aldrich Sep 1998 A
5810724 Gronvall Sep 1998 A
5810734 Caro et al. Sep 1998 A
5817010 Hibl Oct 1998 A
5818985 Merchant et al. Oct 1998 A
5823950 Diab et al. Oct 1998 A
5823952 Levinson et al. Oct 1998 A
5827182 Raley Oct 1998 A
5830131 Caro et al. Nov 1998 A
5830137 Sharf Nov 1998 A
5833618 Caro et al. Nov 1998 A
5839439 Nierlich et al. Nov 1998 A
RE36000 Swedlow et al. Dec 1998 E
5842979 Jarman Dec 1998 A
5851178 Aronow Dec 1998 A
5851179 Ritson et al. Dec 1998 A
5853364 Baker, Jr. et al. Dec 1998 A
5857462 Thomas et al. Jan 1999 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5865736 Baker, Jr. et al. Feb 1999 A
5876348 Sugo Mar 1999 A
5885213 Richardson et al. Mar 1999 A
5890929 Mills et al. Apr 1999 A
5891024 Jarman et al. Apr 1999 A
5904654 Wohltmann et al. May 1999 A
5910108 Solenberger Jun 1999 A
5916154 Hobbs et al. Jun 1999 A
5919133 Taylor Jul 1999 A
5919134 Diab Jul 1999 A
5921921 Potratz et al. Jul 1999 A
5934277 Mortz Aug 1999 A
5934925 Tobler et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5954644 Dettling Sep 1999 A
5978691 Mills Nov 1999 A
5983122 Jarman et al. Nov 1999 A
5995855 Kiani et al. Nov 1999 A
5995856 Mannheimer et al. Nov 1999 A
5995859 Takahashi Nov 1999 A
5997343 Mills et al. Dec 1999 A
5999841 Aoyagi et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6006119 Soller et al. Dec 1999 A
6011986 Diab et al. Jan 2000 A
6014576 Raley Jan 2000 A
6018673 Chin et al. Jan 2000 A
6018674 Aronow Jan 2000 A
6023541 Merchant et al. Feb 2000 A
6027452 Flaherty et al. Feb 2000 A
6036642 Diab et al. Mar 2000 A
6045509 Caro et al. Apr 2000 A
6064898 Aldrich May 2000 A
6067462 Diab et al. May 2000 A
6068594 Schloemer et al. May 2000 A
6073037 Alam et al. Jun 2000 A
6081735 Diab et al. Jun 2000 A
6083172 Baker, Jr. et al. Jul 2000 A
6088607 Diab et al. Jul 2000 A
6094592 Yorkey et al. Jul 2000 A
6104938 Huiku Aug 2000 A
6110522 Lepper, Jr. et al. Aug 2000 A
6112107 Hannula Aug 2000 A
6122042 Wunderman et al. Sep 2000 A
6144868 Parker Nov 2000 A
6151516 Kiani-Azarbayjany et al. Nov 2000 A
6151518 Hayashi Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6154667 Miura et al. Nov 2000 A
6157041 Thomas et al. Dec 2000 A
6157850 Diab et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6184521 Coffin, IV et al. Feb 2001 B1
6206830 Diab et al. Mar 2001 B1
6226539 Potratz May 2001 B1
6229856 Diab et al. May 2001 B1
6230035 Aoyagi et al. May 2001 B1
6236872 Diab et al. May 2001 B1
6253097 Aronow et al. Jun 2001 B1
6256523 Diab et al. Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6272363 Casciani et al. Aug 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6285895 Ristolainen et al. Sep 2001 B1
6285896 Tobler et al. Sep 2001 B1
6298252 Kovach et al. Oct 2001 B1
6304675 Osbourn et al. Oct 2001 B1
6304767 Soller et al. Oct 2001 B1
6321100 Parker Nov 2001 B1
6330468 Scharf Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6341257 Haaland Jan 2002 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6351658 Middleman et al. Feb 2002 B1
6356774 Bernstein et al. Mar 2002 B1
6360114 Diab et al. Mar 2002 B1
6363269 Hanna et al. Mar 2002 B1
6371921 Caro et al. Apr 2002 B1
6374129 Chin et al. Apr 2002 B1
6377828 Chaiken et al. Apr 2002 B1
6377829 Al-Ali Apr 2002 B1
6388240 Schulz et al. May 2002 B2
6393310 Kuenstner May 2002 B1
6397091 Diab et al. May 2002 B2
6397092 Norris et al. May 2002 B1
6397093 Aldrich May 2002 B1
6408198 Hanna et al. Jun 2002 B1
6411833 Baker, Jr. et al. Jun 2002 B1
6415166 Van Hoy et al. Jul 2002 B1
6415233 Haaland Jul 2002 B1
6415236 Kobayashi et al. Jul 2002 B2
6430525 Weber et al. Aug 2002 B1
6434408 Heckel Aug 2002 B1
6441388 Thomas et al. Aug 2002 B1
6453184 Hyogo et al. Sep 2002 B1
6463310 Swedlow et al. Oct 2002 B1
6463311 Diab Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6480729 Stone Nov 2002 B2
6490466 Fein et al. Dec 2002 B1
6497659 Rafert Dec 2002 B1
6501974 Huiku Dec 2002 B2
6501975 Diab et al. Dec 2002 B2
6504943 Sweatt et al. Jan 2003 B1
6505060 Norris Jan 2003 B1
6505061 Larson Jan 2003 B2
6505133 Hanna Jan 2003 B1
6510329 Heckel Jan 2003 B2
6515273 Al-Ali Feb 2003 B2
6519486 Edgar, Jr. et al. Feb 2003 B1
6519487 Parker Feb 2003 B1
6522398 Cadell et al. Feb 2003 B2
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6526301 Larsen et al. Feb 2003 B2
6528809 Thomas et al. Mar 2003 B1
6537225 Mills Mar 2003 B1
6541756 Schulz et al. Apr 2003 B2
6542764 Al-Ali et al. Apr 2003 B1
6546267 Sugiura Apr 2003 B1
6553241 Mannheimer et al. Apr 2003 B2
6564077 Mortara May 2003 B2
6571113 Fein et al. May 2003 B1
6580086 Schulz et al. Jun 2003 B1
6582964 Samsoondar et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6584413 Keenan et al. Jun 2003 B1
6591123 Fein et al. Jul 2003 B2
6594511 Stone et al. Jul 2003 B2
6595316 Cybulski et al. Jul 2003 B2
6597933 Kiani et al. Jul 2003 B2
6600940 Fein et al. Jul 2003 B1
6606509 Schmitt Aug 2003 B2
6606510 Swedlow et al. Aug 2003 B2
6606511 Ali et al. Aug 2003 B1
6611698 Yamashita et al. Aug 2003 B1
6614521 Samsoondar et al. Sep 2003 B2
6615064 Aldrich Sep 2003 B1
6615151 Scecina et al. Sep 2003 B1
6618602 Levin Sep 2003 B2
6622095 Kobayashi et al. Sep 2003 B2
6628975 Fein et al. Sep 2003 B1
6631281 Kastle Oct 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6640116 Diab Oct 2003 B2
6643530 Diab et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654623 Kastle Nov 2003 B1
6654624 Diab et al. Nov 2003 B2
6657717 Cadell et al. Dec 2003 B2
6658276 Kianl et al. Dec 2003 B2
6658277 Wasserman Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6662033 Casciani et al. Dec 2003 B2
6665551 Suzuki Dec 2003 B1
6668183 Hicks et al. Dec 2003 B2
6671526 Aoyagi et al. Dec 2003 B1
6671531 Al-Ali et al. Dec 2003 B2
6675031 Porges et al. Jan 2004 B1
6675106 Keenan et al. Jan 2004 B1
6678543 Diab et al. Jan 2004 B2
6681126 Solenberger Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6687620 Haaland et al. Feb 2004 B1
6694157 Stone et al. Feb 2004 B1
6697655 Sueppel et al. Feb 2004 B2
6697656 Al-Ali Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6701170 Stetson Mar 2004 B2
6708049 Berson et al. Mar 2004 B1
6711503 Haaland Mar 2004 B2
6714803 Mortz Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
6714805 Jeon et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6719705 Mills Apr 2004 B2
6720734 Norris Apr 2004 B2
6721584 Baker, Jr. et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725074 Kastle Apr 2004 B1
6725075 Al-Ali Apr 2004 B2
6726634 Freeman Apr 2004 B2
6735459 Parker May 2004 B2
6741875 Pawluczyk et al. May 2004 B1
6741876 Scecina et al. May 2004 B1
6743172 Blike Jun 2004 B1
6745060 Diab et al. Jun 2004 B2
6745061 Hicks et al. Jun 2004 B1
6748253 Norris et al. Jun 2004 B2
6748254 O'Neil et al. Jun 2004 B2
6754515 Pologe Jun 2004 B1
6754516 Mannheimer Jun 2004 B2
6760607 Al-All Jul 2004 B2
6760609 Jacques Jul 2004 B2
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6773397 Kelly Aug 2004 B2
6778923 Norris et al. Aug 2004 B2
6780158 Yarita Aug 2004 B2
6788849 Pawluczyk Sep 2004 B1
6792300 Diab et al. Sep 2004 B1
6801797 Mannheimer et al. Oct 2004 B2
6801799 Mendelson Oct 2004 B2
6810277 Edgar, Jr. et al. Oct 2004 B2
6813511 Diab et al. Nov 2004 B2
6816741 Diab Nov 2004 B2
6819950 Mills Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6825619 Norris Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6829496 Nagai et al. Dec 2004 B2
6830711 Mills et al. Dec 2004 B2
6836679 Baker, Jr. et al. Dec 2004 B2
6839579 Chin Jan 2005 B1
6839580 Zonios et al. Jan 2005 B2
6839582 Heckel Jan 2005 B2
6842702 Haaland et al. Jan 2005 B2
6845256 Chin et al. Jan 2005 B2
6847835 Yamanishi Jan 2005 B1
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6852083 Caro et al. Feb 2005 B2
6861639 Al-Ali Mar 2005 B2
6869402 Arnold Mar 2005 B2
6882874 Huiku Apr 2005 B2
6898452 Al-Ali et al. May 2005 B2
6912049 Pawluczyk et al. Jun 2005 B2
6917422 Samsoondar et al. Jul 2005 B2
6919566 Cadell Jul 2005 B1
6920345 Al-Ali et al. Jul 2005 B2
6921367 Mills Jul 2005 B2
6922645 Haaland et al. Jul 2005 B2
6928311 Pawluczyk et al. Aug 2005 B1
6931268 Kiani-Azarbayjany et al. Aug 2005 B1
6931269 Terry Aug 2005 B2
6934570 Kiani et al. Aug 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6943348 Coffin, IV Sep 2005 B1
6944487 Maynard et al. Sep 2005 B2
6950687 Al-Ali Sep 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6975891 Pawluczyk Dec 2005 B2
6979812 Al-Ali Dec 2005 B2
6985764 Mason et al. Jan 2006 B2
6987994 Mortz Jan 2006 B1
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
6999904 Weber et al. Feb 2006 B2
7001337 Dekker Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7006856 Baker, Jr. et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7024233 Al et al. Apr 2006 B2
7027849 Al-Ali Apr 2006 B2
7030749 Al-Ali Apr 2006 B2
7039449 Al-Ali May 2006 B2
7041060 Flaherty et al. May 2006 B2
7044918 Diab May 2006 B2
20010044700 Koboyashi et al. Nov 2001 A1
20010045532 Schulz et al. Nov 2001 A1
20020021269 Rast Feb 2002 A1
20020038078 Ito Mar 2002 A1
20020038081 Fein et al. Mar 2002 A1
20020059047 Haaland May 2002 A1
20020111748 Kobayashi et al. Aug 2002 A1
20020156353 Larson Oct 2002 A1
20020161291 Kiani et al. Oct 2002 A1
20020183819 Struble Dec 2002 A1
20030109775 O'Neil et al. Jun 2003 A1
20030120160 Yarita Jun 2003 A1
20030139657 Solenberger Jul 2003 A1
20030195402 Fein et al. Oct 2003 A1
20040006261 Swedlow et al. Jan 2004 A1
20040033618 Haass et al. Feb 2004 A1
20040034898 Al Ali et al. Feb 2004 A1
20040059209 Al Ali et al. Mar 2004 A1
20040064259 Haaland et al. Apr 2004 A1
20040081621 Arndt et al. Apr 2004 A1
20040092805 Yarita May 2004 A1
20040133087 Ali et al. Jul 2004 A1
20040138538 Stetson Jul 2004 A1
20040138540 Baker, Jr. et al. Jul 2004 A1
20040147823 Kiani et al. Jul 2004 A1
20040158134 Diab et al. Aug 2004 A1
20040158135 Baker, Jr. et al. Aug 2004 A1
20040162472 Berson et al. Aug 2004 A1
20040167382 Gardner et al. Aug 2004 A1
20040176670 Takamura et al. Sep 2004 A1
20040181134 Baker, Jr. et al. Sep 2004 A1
20040199063 O'Neil et al. Oct 2004 A1
20040204639 Casciani et al. Oct 2004 A1
20040204868 Maynard et al. Oct 2004 A1
20040262046 Simon et al. Dec 2004 A1
20040267103 Li et al. Dec 2004 A1
20040267140 Ito et al. Dec 2004 A1
20050011488 Al Ali et al. Feb 2005 A1
20050043902 Haaland et al. Feb 2005 A1
20050049469 Aoyagi et al. Mar 2005 A1
20050070773 Chin et al. Mar 2005 A1
20050070775 Chin et al. Mar 2005 A1
20050075546 Samsoondar et al. Apr 2005 A1
20050085735 Baker, Jr. et al. Apr 2005 A1
20050124871 Baker, Jr. et al. Jun 2005 A1
20050143634 Baker, Jr. et al. Jun 2005 A1
20050143943 Brown Jun 2005 A1
20050148834 Hull et al. Jul 2005 A1
20050184895 Petersen et al. Aug 2005 A1
20050187447 Chew et al. Aug 2005 A1
20050187448 Petersen et al. Aug 2005 A1
20050187449 Chew et al. Aug 2005 A1
20050187450 Chew et al. Aug 2005 A1
20050187452 Petersen et al. Aug 2005 A1
20050187453 Petersen et al. Aug 2005 A1
20050197549 Baker, Jr. Sep 2005 A1
20050197579 Baker, Jr. Sep 2005 A1
20050197793 Baker, Jr. Sep 2005 A1
20050203357 Debreczeny et al. Sep 2005 A1
20050228253 Debreczeny Oct 2005 A1
20050250997 Takedo et al. Nov 2005 A1
20060030764 Porges et al. Feb 2006 A1
Foreign Referenced Citations (3)
Number Date Country
WO 9843071 Oct 1998 WO
WO 0059374 Oct 2000 WO
WO 03068060 Aug 2003 WO
Related Publications (1)
Number Date Country
20060211925 A1 Sep 2006 US
Provisional Applications (4)
Number Date Country
60657596 Mar 2005 US
60657281 Mar 2005 US
60657268 Mar 2005 US
60657759 Mar 2005 US